Company ProfilePremium

Meilleure Health International Industry Group Limited

Company Profile Analysis

Ticker: 2327.HK美瑞健康國際產業集團有限公司

ESOMAR 23 Corporate BadgeISO Certifications Badge
Meilleure Health International Industry Group Limited - Company showcase

Year Founded & Workforce

1987

43 Employees

Meilleure Health International Industry Group Limited logo

Meilleure Health International Industry Group Limited Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

Meilleure Health International Industry Group Limited Overview

Meilleure Health is a controlled, micro-cap Hong Kong holding company whose public identity is "health" but whose economic substance is overwhelmingly property and lending. Reported revenue in FY2025 was only HK$36.5m, of which rental income from PRC investment properties contributed more than half, while interest earned on a HK$491m loan book (HK$29.3m) was nearly as large as total gross profit [AR25]. Its healthcare activities — functional-medicine clinics in Shenzhen and Nanjing, the Jixiaojian medical-aesthetics-plus-skincare brand, the Swiss CBD brand AlpReleaf and minority stakes in cell-therapy developers Wingor Bio and Mei Ai Kang — generated HK$16.1m of revenue and a segment loss. A 109-unit townhouse project in Alphington, Melbourne began handing over units in H1 2026, lifting interim revenue nine-fold to HK$164.6m [IR26]. The shares trade at roughly 0.65x book, with the Zhou family controlling around 56–60% of the equity.


The company's own description

[AR25] defines the Group's principal activities as healthcare-related business, trading of construction materials and renewable energy products, real estate agency services, property investment and leasing, development of residential properties, and procurement services for renewable energy products. Management frames its long-run ambition around China's "Healthy China 2030" policy, with skin health management as the strategic anchor, cell therapy and health management as synergistic innovation areas, and a stated aspiration to move from selling health products to exporting health concepts. The corporate vision repeated in both [AR25] and [IR26] is "using technology and expertise to serve more people's health and beauty needs."

Independent characterisation

On the evidence of the financial statements, Meilleure Health is best characterised as a family-controlled investment holding company with four economic engines of very different weight:

  1. PRC investment property landlord — HK$678.3m of investment properties at fair value (30 Jun 2026), all situated in the PRC and held on medium-term leases, generating HK$19.2m of rent in FY2025 (≈2.9% gross yield on the year-end fair value of HK$663.4m) [AR25], [IR26]. HK$509.1m of these properties are pledged to banks [IR26].

  2. Lender — a HK$441.2m loan book at 30 Jun 2026 (HK$491.2m at end-2025), more than half of which (HK$230.7m, 52.3%) is owed by U-light Energy (Guangyu Zhaoneng New Energy Group), a related party in which the Group holds 3.168%, at one-year LPR + 3.05% and guaranteed personally by the controlling shareholder; the remainder is unsecured short-term loans to eight independent borrowers at 3–8% [IR26]. Interest income (HK$29.3m in FY2025) exceeded rental income [AR25].

  3. Residential developer (Australia) — a wholly-owned 109-townhouse project on an 11,488 sq.m. site at 626 Heidelberg Road, Alphington, VIC (6.5 km from Melbourne CBD; GFA ≈18,752 sq.m.), marketed as "Yarrabend", built with Level 10 Pty Ltd and designed by Rothelowman; pre-sales started November 2022 and first-phase handovers began in H1 2026, producing HK$151.9m of property-sale revenue at a low (≈13%) gross margin [AR25], [IR26].

  4. Healthcare and consumer health — clinics, aesthetics services, skincare and CBD products (HK$16.1m revenue in FY2025; HK$4.4m in H1 2026), plus equity-accounted and FVTPL stakes in cell-therapy companies held within the "equity investment" segment [AR25], [IR26].

A residual trading business (construction materials, renewable-energy products and procurement services) has shrunk from HK$149m of revenue in FY2021 to HK$1.2m in FY2025 and HK$0.1m in H1 2026 [SA], [AR25], [IR26].

Revenue model mix

Revenue model (FY2025, HKD Mn)AmountShare of revenue
Lease/rental (recurring) — investment properties19.252.6%
Product sales — healthcare-related products9.425.8%
Services — aesthetic medical5.414.9%
Services — healthcare management1.33.6%
Agency/commission — healthcare product sale agency0.82.2%
Services — renewable energy procurement0.41.0%
Total revenue36.5100.0%

Source: [AR25] Note 4. Note that interest income (HK$29.3m) and fair-value gains on investment properties (HK$21.7m) are recorded outside revenue but are central to the profit model.

In H1 2026 the mix inverted: sale of completed properties (HK$151.9m) was 92.3% of revenue, rental 5.0%, healthcare 2.6% [IR26].

Value chain position, customers, end-markets

Property: owner-landlord of PRC commercial units (several acquired from vehicles connected to the controlling shareholder, e.g., Yuye Tianyi Commercial Plaza units in Kunshan); developer-seller to retail homebuyers in Melbourne.

Lending: provider of short-term working-capital loans to corporates and individuals sourced through management's networks [AR25].

Healthcare: downstream consumer-facing services (clinics, aesthetics) and branded consumer products sold through clinics, a medical-aesthetics chain partner (BeauCare Clinics), livestreamers on Taobao, Douyin and Xiaohongshu, and European distribution for AlpReleaf (22 countries) [AR25].

Customers: consumers (aesthetics, health management, CBD), PRC tenants (commercial leasing), Australian homebuyers, corporate borrowers; geographically 96% PRC in FY2025 revenue, shifting to Australia in 2026 [AR25], [IR26].

Strategy

Stated strategy themes (paraphrased from [AR25] and [IR26])

Skin health management as strategic anchor: keep refining the Jixiaojian products and model combining efficacy skincare with medical aesthetics; integrate online and offline channels; build a "scientific skincare brand".

Cell therapy and health management synergy: deepen R&D and application presence via Wingor Bio and Mei Ai Kang and explore commercialisation pathways that link to the clinics.

  • Dual engines of technology R&D and brand value, aiming to transform the group from a provider of products into a provider of health concepts.

Overseas expansion: strengthen AlpReleaf channels in Europe and complete the Australian townhouse project.

Opportunistic diversification: explore businesses with stable cash flows or high growth potential (the Jiangsu Yide rental acquisition is the clearest recent example).

Shareholder returns: dividends and buybacks explicitly cited as ongoing tools [IR26].

Initiatives in the last 24 months

DateInitiativeDetail / target
31 Jan 2024 onwardU-light Energy revolving facilityUp to RMB200m at LPR+3.05%, drawdown period to 31 Dec 2026; HK$230.7m outstanding at 30 Jun 2026
Nov 2024Kunshan commercial units acquisitionRMB13.4m, rental property
Jan 2025Accelerated Australian sell-down incl. sale to CEOAUD1.36m unit; expected gain ≈AUD249k [DT25 press coverage]
2,025Share repurchases29.706m shares, HK$8.85m [AR25]
Aug 2025Introduction of interim dividendHK0.15 cents, repeated in Aug 2026
Jan 2026Buyback programmeUp to 10% of shares under June 2025 mandate
Jan 2026Jiangsu Yide acquisitionRMB124.767m; ≈RMB7.8m annual rent (≈5.97% yield)
Apr 20262026 Share Award SchemeEmployee/director incentive
H1 2026Alphington handoversFirst phase delivered; HK$151.9m revenue

ESG/sustainability commitments: none quantified in the announcements reviewed. Cost programmes: none announced; operating expenses broadly flat at ≈HK$31m (FY2024–FY2025). Medium-term financial targets / guidance: not provided; the company issues only profit alerts as required by the Listing Rules.

Products & Services

Pricing models are not publicly disclosed for any product line unless noted.

Healthcare-related segment

OfferingDescription & capabilitiesTarget customerLaunch / statusDisclosed flagship elements
Shenzhen high-end health management clinicInternational-standard health management grounded in functional medicine; operated by an experienced professional teamAffluent urban PRC consumersShenzhen anti-ageing/health management advisory centre planned for H2 2017; operating "steadily" per [IR26]Client-retention emphasis; management-system optimisation
Nanjing high-end health management clinicAs aboveAffluent consumers in JiangsuOperating per [AR25], [IR26]—
Healthcare management services (revenue line)Over-time service revenueClinic membersFY2025 revenue HK$1.3m (FY2024: HK$4.5m); H1 2026 HK$1.16m—
Jixiaojian (肌小簡) brandCurated brand combining light medical aesthetics and efficacy skincare; regimen positioned as 60% non-invasive aesthetic treatment + 40% simplified skincareYounger PRC consumers seeking light medical aestheticsLaunched H2 2021Photoelectric repair series; medical-grade dressing series; exosome-based premium anti-ageing series
Jixiaojian medical aesthetics clinicSignature "Jixiaojian × Super Photon" protocol covering pre-, intra- and post-treatment careAesthetics clientsOperating "for years" [AR25]Clinical demonstration base for Lumenis; Peninsula Medical (半島) soothing device project
Aesthetic medical services (revenue line)Point-in-time service revenue—FY2025 HK$5.4m (FY2024 HK$7.6m); H1 2026 HK$1.5m—
Healthcare-related products (revenue line)Skincare and health productsConsumers via clinics, BeauCare Clinics, livestream channelsFY2025 HK$9.4m (FY2024 HK$7.5m); H1 2026 HK$1.4mRaw materials from DSM and Ashland; supramolecular lab with Shinehigh Innovation; recombinant collagen partnership with Jland Biotech
AlpReleafPremium CBD health and wellness brand developed and produced in Switzerland; lines for relaxation, sleep support and muscle soreness reliefEuropean consumersLaunched 2021; EU and UK certification; access to 22 European countries—
CBD downstream products (revenue line)——FY2025 nil (FY2024 HK$9k); H1 2026 HK$0.26m—

Trading segment

OfferingDescriptionStatus / revenue
Construction materials tradingBulk construction materials sold in the PRCHK$10.5m in FY2024; nil in FY2025 [AR25]
Renewable energy products saleSale of renewable energy productsHK$1.05m FY2024; nil FY2025; HK$0.1m H1 2026
Renewable energy procurement servicesProcurement on behalf of customers; prepayments and performance bonds placed with suppliers to secure pricing for 2–3 yearsHK$0.36m FY2025 (FY2024 HK$1.0m); prepayments to suppliers HK$45.3m at 30 Jun 2026
Healthcare product sale agencyCommission-based agencyHK$0.8m FY2025; nil H1 2026

Property-related segment

Asset / serviceDescriptionKey data
PRC investment property portfolioCommercial properties in the PRC held for rental, valued by income (term and reversion) and direct comparison approachesFair value HK$663.4m (end-2025), HK$678.3m (30 Jun 2026); rental income HK$19.2m FY2025, HK$8.2m H1 2026
Kunshan units (Yuye Tianyi Commercial Plaza)Units 7 and 12, 1/F, Tower 13, 65 Jintang Road, Zhoushi Town, Kunshan; 514.54 sq.m.Acquired for RMB13.4m (agreement 29 Nov 2024) [MS]
Alphington / "Yarrabend" townhouses109 townhouses, site 11,488 sq.m., GFA ≈18,752 sq.m., Lot A & B 626 Heidelberg Road, Alphington VIC 3078Carrying value HK$310.6m at 30 Jun 2026; H1 2026 sales HK$151.9m; construction commitments HK$61.5m [IR26]
Real estate agency servicesListed as a principal activityRevenue not separately disclosed in FY2025
Jiangsu Yide (pending/proposed)PRC equity-investment and property-leasing company; properties mostly leased; annual rent ≈RMB7.8m (≈5.97% yield on consideration)Consideration RMB124.767m; approved at SGM 21 Apr 2026 [JY26], [SGM26]

Equity investment segment (principal holdings disclosed)

HoldingNatureDisclosed facts
Shenzhen Wingor Biotechnology (Wingor Bio, 深圳市茵冠生物科技)Cell therapy (stem cells, immune cells, exosomes, "genetic engineering +"); National High-Tech EnterpriseStake acquired 2019, partly sold 2021 (consideration receivable by 2028); 7 cell-drug IND applications accepted by NMPA; 3 approved into clinical trials, incl. WG103 (umbilical-cord MSC for acute ischaemic stroke, Phase II from Jul 2025) and an MSC injection for premature ovarian insufficiency (Jan 2026) [AR25], [IR26]
Beijing Mei Ai Kang Technology (北京美艾康)Cellular immunotherapyEstablished 2020; clinical studies with PLA General Hospital Fifth Medical Centre and others; 132 clinical experiments completed; self-transfusion injector patent approved [AR25]
U-light Energy (Guangyu Zhaoneng New Energy Group)Renewable energy; related party3.168% held via Wuhu Ruima at 30 Jun 2026 (3.636% at end-2025) [IR26], [AR25]
Joint venture (unnamed in announcements)Equity-accountedCarrying value HK$31.3m at 30 Jun 2026 (HK$46.4m end-2025); partial disposals generated gains in FY2025 and H1 2026
AssociatesEquity-accountedHK$3.7m at 30 Jun 2026; HK$11.0m capital contribution commitment
Total investment portfolio—HK$80.4m at 30 Jun 2026 (HK$95.2m end-2025); no single holding >5% of total assets [IR26]

Treasury/lending "product"

Short-term interest-bearing loans and a long-term revolving facility are offered to identified corporate and individual borrowers to raise returns on cash [AR25]. Terms at 30 Jun 2026: 3–8% fixed for independent borrowers; LPR+3.05% for U-light Energy [IR26].

Financial Narrative

Methodology: FY2024–FY2025 income statement items from [AR25]; FY2021–FY2023 from [SA] (S&P standardised; FY2022 revenue and gross profit match [AR22]). Operating income and EBITDA are S&P-standardised (gross profit less selling, admin and other operating expenses) for all years because the company does not report an operating-profit line. Note: [SA] shows FY2024 gross profit of HK$27.95m vs company-reported HK$28.905m; company figure used.

Income statement

EPS for FY2024–FY2025 as reported [AR25]; FY2021–FY2023 derived from [SA] net income and weighted shares (4,257m; 4,109m; 4,093m basic). DPS: FY2025 = HK0.15 cents interim + HK0.4 cents final [AR25]; FY2022 HK1.6 cents implied by HK$65.5m paid in 2023 [SA]; FY2021 no dividend per [SA].

Margins and growth (%)

Revenue CAGR FY2021–FY2025: −38.4% per annum (HK$253.0m to HK$36.5m). Net income CAGR FY2021–FY2025: −10.9% per annum.

Commentary. The five-year record is one of steep revenue contraction masked by resilient bottom-line profit. Revenue collapsed by 86% over four years as the low-margin trading business (59% of FY2021 revenue) was run down and healthcare demand weakened under what management repeatedly calls "adverse market conditions" in the PRC [AR25]. Gross margin rose mechanically from 40% to 62% because the residual mix is dominated by rental income. From FY2024, operating expenses (≈HK$31m a year of selling and admin costs) exceeded gross profit, producing S&P-basis operating losses. Profit has nonetheless held at HK$32–41m in three of the last four years because of three non-operating pillars: interest income on the loan book (HK$29.3m in FY2025), annual fair-value uplifts on PRC investment property (HK$13.6–23.8m every year), and FX gains (HK$8.4m in FY2025). FY2025's net margin above 100% further reflects an HK$7.5m tax credit, including HK$5.3m of prior-year PRC over-provision [AR25]. The quality of earnings is therefore low: in FY2025 roughly HK$59m of the HK$30.5m pre-tax profit came from interest, revaluation and FX, offset by core operating losses, impairments and finance costs.

The H1 2026 inflection changes the revenue profile but not the margin structure: revenue of HK$164.6m (vs HK$17.5m), gross margin of 17.3% (vs 81.1%), and a property sales gross profit of about HK$20.3m on HK$151.9m of sales (≈13% margin) [IR26]. TTM revenue to June 2026 was HK$183.6m and TTM net income HK$51.2m [SA].

Balance sheet

Sources: FY2024–FY2025 [AR25]; FY2021–FY2023 [SA]. At 30 Jun 2026: total assets HK$1,786.1m; cash HK$7.8m; bank borrowings HK$291.0m (HK$193.2m current, HK$97.7m non-current); total equity HK$1,303.0m; investment properties HK$678.3m [IR26].

Company-defined gearing: net debt (borrowings plus trade payables, contract liabilities, accruals, related-party balances, dividend payable, less cash and restricted deposits) / (equity + net debt) = 26.4% at end-2025 (21.6% end-2024) and 21.3% at 30 Jun 2026; company-defined net debt HK$447.1m (end-2025) and HK$352.4m (30 Jun 2026) [AR25], [IR26].

Commentary. The balance sheet is asset-rich but liquidity-thin. Equity drifted down 13% from HK$1,431m (FY2021) to HK$1,201m (FY2024) — buybacks, dividends and RMB/AUD translation losses outweighed profits — then recovered on FX gains in FY2025 and H1 2026. Cash fell from HK$273m to HK$8m over 4.5 years as cash was redeployed into (a) the loan book (HK$491m at end-2025), (b) Australian development spend (properties under development rose from HK$255m to HK$373m during FY2025), and (c) PRC property acquisitions. Debt rose from HK$170m to HK$381m before falling to HK$291m on Australian settlement proceeds in H1 2026. The group had no unutilised banking facilities at end-2025 or 30 Jun 2026, and HK$637.1m of assets were pledged [AR25], [IR26]. The current ratio looks comfortable only because the loan book and properties under development sit in current assets; the quick ratio is about 0.11 [SA].

Cash flow

Sources: [SA]; FY2025 operating, investing and financing cash flows match [AR25]. H1 2026: operating cash inflow HK$16.1m, investing inflow HK$87.0m (incl. HK$68.5m loan repayments), financing outflow HK$108.7m (incl. HK$146.1m debt repayment) [IR26].

Commentary. Operating cash flow is volatile and driven by working-capital swings in loan receivables (classified partly in operating activities by S&P), Australian construction spend and receivables. FY2024's HK$186m inflow reflected collection of receivables; FY2025's HK$50m outflow reflected HK$92.6m of capitalised development expenditure [AR25]. Across FY2021–FY2025, cumulative FCF was approximately −HK$50m while cumulative shareholder distributions (dividends plus buybacks) were about HK$191m and net borrowing about HK$238m — i.e., distributions have effectively been debt-funded or funded by drawing down the large FY2021 cash pile.

Ratios

Computed from 6.1 and 6.3. Net debt/EBITDA: net cash in FY2021; 1.2x in FY2022; 5.2x in FY2023; not meaningful in FY2024–FY2025 because S&P-basis EBITDA was negative. Cash conversion cycle: not meaningful for this business mix (inventories are almost entirely development property, and revenue is dominated by rent); not calculated.

Commentary. Returns on capital are structurally low — ROE has not exceeded 4.2% in five years, and the only reason it is positive is revaluation, interest and FX income. A business with HK$1.25bn of equity generating HK$30–40m of profit trades, logically, at a deep discount to book (0.65x currently). Coverage looks acceptable only when non-operating income is included; on an operating basis, the company has not covered its interest bill since FY2023.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Segment Overview

SegmentContentsProducts / services

Healthcare-related business

Health management services, aesthetic medical services, sale of healthcare-related and CBD downstream products

Shenzhen and Nanjing functional-medicine clinics; Jixiaojian clinic and skincare; AlpReleaf CBD (Switzerland/Europe)

Trading business

Trading of construction materials and renewable energy products; procurement services for renewable energy products; healthcare-related product sale agency services

Construction materials (nil in FY2025); renewable energy products; procurement services; agency commissions

Property-related business

Real estate agency services, leasing of investment properties, development and sale of residential properties

PRC investment property portfolio; Alphington (Melbourne) townhouses

Equity investment business

Management of investment portfolio

Wingor Bio and other FVTPL holdings, joint venture and associates, FVTOCI equities, derivatives

Segment revenue (HKD Mn)

Segment revenue (HKD Mn)FY2021FY2022FY2023FY2024FY2025

Healthcare-related (incl. industrial hemp)

52.7053.7848.1519.6116.15

Trading

149.0637.1362.5713.821.17

Property-related

51.2828.9818.5917.2419.20

Equity investment

00000

Total revenue

253.03119.89129.3050.6836.52

Segment share of revenue (%)

Segment share of revenue (%)FY2021FY2022FY2023FY2024FY2025

Healthcare-related

20.844.937.238.744.2

Trading

58.931.048.427.33.2

Property-related

20.324.214.434.052.6

Segment revenue YoY growth (%)

Segment revenue YoY growth (%)FY2022FY2023FY2024FY2025

Healthcare-related

2.0-10.5-59.3-17.7

Trading

-75.168.5-77.9-91.5

Property-related

-43.5-35.9-7.311.4

Revenue by Segment and Segment Assets & Liabilities

Segment result (HKD Mn)FY2024FY2025

Healthcare-related

-19.31-4.15

Trading

7.18-4.37

Property-related

39.5831.88

Equity investment

15.61-9.72

Total segment result

43.0513.65

Segment assets (HKD Mn)

Segment assets (HKD Mn)FY2024FY2025

Healthcare-related

13.1323.59

Trading

90.5048.35

Property-related

929.541,085.91

Equity investment

116.42106.94

Unallocated corporate (incl. loan book)

487.59519.58

Deferred tax assets

31.4631.22

Consolidated total assets

1,668.651,815.59

Segment Revenue

Segment (six months)H1 2025 revenueH1 2026 revenueH1 2025 resultH1 2026 result

Healthcare-related

6.604.350.07-0.14

Trading

0.810.10-1.020.79

Property-related

10.04160.136.0620.76

Equity investment

00-0.84-2.62

Total

17.45164.574.2618.79

Income Statement and Per-Share Data

MetricFY2021FY2022FY2023FY2024FY2025

Revenue (HKD Mn)

253.03119.89129.3050.6836.52

Gross profit (HKD Mn)

100.9366.7677.2128.9122.63

Operating income, S&P basis (HKD Mn)

57.3530.8335.38-3.85-9.71

EBITDA, S&P basis (HKD Mn)

58.3932.2636.93-2.67-8.97

Interest and investment income (HKD Mn)

13.5427.2119.8722.5029.30

Fair value gains on investment properties (HKD Mn)

15.1813.5818.5423.8121.73

Finance costs (HKD Mn)

8.3911.4511.4110.299.29

Profit before tax (HKD Mn)

85.7025.3952.9845.4030.54

Income tax expense (HKD Mn)

25.257.6114.4913.36-7.46

Net income attributable to owners (HKD Mn)

60.3217.8240.8332.4837.98

EPS basic (HK cents)

1.420.431.000.790.93

EPS diluted (HK cents)

1.410.431.000.790.93

Dividend per share declared (HK cents)

01.60.40.40.55

Margin Analysis (%)

MetricFY2021FY2022FY2023FY2024FY2025

Gross margin (%)

39.955.759.757.062.0

Operating margin, S&P basis (%)

22.725.727.4-7.6-26.6

EBITDA margin (%)

23.126.928.6-5.3-24.6

Pre-tax margin (%)

33.921.241.089.683.6

Net margin (%)

23.814.931.664.1104.0

Revenue growth YoY (%)

-4.6-52.67.8-60.8-27.9

Balance Sheet

MetricFY2021FY2022FY2023FY2024FY2025

Total assets (HKD Mn)

1,7371,7111,6971,6691,816

Cash and equivalents (HKD Mn)

272.59210.99106.3129.9413.08

Cash plus short-term investments (HKD Mn)

380.39210.99106.3129.9413.08

Short-term bank borrowings (HKD Mn)

58.3478.24159.3083.18271.32

Long-term bank borrowings (HKD Mn)

110.36165.20137.32218.65109.08

Total debt incl. leases (HKD Mn)

170.42249.13297.06303.06380.96

Net debt, debt minus cash and ST investments (HKD Mn)

-209.9738.14190.75273.12367.88

Total equity (HKD Mn)

1,4311,3271,2541,2011,248

Goodwill and intangibles (HKD Mn)

18.5718.5418.5000

Investment properties (HKD Mn)

000610.29663.39

Working capital (HKD Mn)

764.81785.08694.79529.95654.25

Cash Flow

MetricFY2021FY2022FY2023FY2024FY2025

Operating cash flow (HKD Mn)

-83.2743.15-136.49186.00-50.02

Capital expenditure (HKD Mn)

-6.48-1.01-0.83-0.13-0.58

Free cash flow (HKD Mn)

-89.7542.14-137.32185.86-50.60

Investing cash flow (HKD Mn)

161.56-134.7653.72-253.9814.64

Financing cash flow (HKD Mn)

-38.2241.93-18.90-6.3918.07

Dividends paid (HKD Mn)

0065.5016.3822.52

Share buybacks (HKD Mn)

40.6837.020.3408.86

Net new borrowing (HKD Mn)

10.7490.0658.1720.2558.70

Returns & Leverage Ratios (%) and Financial Ratios (x)

MetricFY2021FY2022FY2023FY2024FY2025

ROE, on year-end equity (%)

4.21.33.32.73.0

ROA, on year-end assets (%)

3.51.02.41.92.1

Pre-tax ROIC, EBIT / (equity + debt) (%)

3.62.02.3-0.3-0.6

Current ratio (x)

7.906.734.104.352.81

Debt to equity (x)

0.120.190.240.250.31

Interest coverage, EBIT / finance costs (x)

6.842.693.10-0.37-1.05

Interest coverage, (PBT + finance costs) / finance costs (x)

11.23.25.65.44.3

Asset turnover, revenue / total assets (x)

0.1460.0700.0760.0300.020

Region revenue (HKD Mn)

Region revenue (HKD Mn)FY2024FY2025

PRC

46.5235.10

Hong Kong

00.22

Europe

2.871.20

Others

1.290

Total

50.6836.52

Region growth YoY (%)

Region growth YoY (%)FY2025

PRC

-24.5

Europe

-58.3

Six Months to 30 Jun 2026 Details

Six months to 30 Jun 2026 (HKD Mn)HealthcarePropertyTradingTotal

PRC

4.09004.09

Australia

0151.940151.94

Others

0.2600.100.36

Total (excl. rental income HK$8.18m, PRC)

4.35151.940.10156.39

Six months to 30 Jun 2025 (HKD Mn)

Healthcare

Trading

Total

—

PRC

6.4206.42—

Others

0.180.810.99—

Total (excl. rental income HK$10.04m, PRC)

6.600.817.41—

Non-current assets by location (HKD Mn)

Non-current assets by location (HKD Mn)FY2024FY2025

PRC

668.98717.07

Hong Kong

0.010.01

Europe

0.020.01

Valuation Snapshot

MetricValueSource

Last price

HK$0.208 (9 Oct 2026)

[SA]

52-week change

−27.0%

[SA]

50-day / 200-day moving average

HK$0.23 / HK$0.26

[SA]

Beta (5-year)

0.12

[SA]

Average daily volume (20 days)

≈225,600 shares

[SA]

Approx. 3-year change (vs implied end-2023 ≈HK$0.246)

≈−15% (implied; approximate)

Derived from [SA] P/S and revenue

Approx. 5-year change (vs implied end-2021 ≈HK$0.48)

≈−57% (implied; approximate)

Derived from [SA] P/S and revenue

Implied year-end share price (HKD)

FY2021

FY2022

Implied price (HK$, from aggregator P/S x revenue / shares)

0.480.29

Valuation Multiples

MultipleMeilleure HealthPeer comparison

P/E (TTM)

16.6x

Peer multiples not compiled/verified

P/B

0.65x—

EV/Sales (TTM)

6.1x—

EV/EBITDA

Not meaningful (TTM EBITDA ≈HK$1.5m)

—

Earnings yield

6.1%—

Dividend yield (trailing)

2.64%—

Dividend per share (HK cents)

Dividend per share (HK cents)FY2021FY2022FY2023FY2024FY2025

Interim

00000.15

Final

01.60.40.40.4

Total

01.60.40.40.55

Dividends & Capital Returns

Buyback activityFY2021FY2022FY2023FY2024FY2025

Buyback cash outflow (HKD Mn)

40.6837.020.3408.86

Capital Markets Data

Bank borrowings maturity (HKD Mn)31 Dec 202431 Dec 202530 Jun 2026

Within 1 year

83.18271.32193.23

1–2 years

120.9733.4335.08

2–5 years

66.9851.2842.07

Over 5 years

30.6924.3720.59

Total

301.82380.40290.97

Analyst Conclusions

Management guidance

No quantitative guidance. Management expresses confidence, cites net current assets of HK$702.0m at 30 Jun 2026, and commits to skin-health focus, prudent exploration of new growth avenues, overseas expansion and continued capital returns [IR26]. Consensus growth expectations: not available (no coverage).

Bull case

  1. Deep discount to tangible book with a monetisation catalyst: shares trade at ≈0.65x book; the remaining HK$310.6m of Alphington inventory and HK$441m of short-dated loans could convert to cash, reduce debt and support larger distributions.

  2. Rising recurring income base: rental income plus the Jiangsu Yide addition (≈RMB7.8m a year) and LPR-linked interest could lift recurring pre-tax income even without healthcare improvement.

  3. Free option on cell therapy: Wingor Bio's seven INDs and Phase II stroke programme, in a policy environment that formalised cell-therapy regulation in 2025, could crystallise value well above the HK$80m portfolio carrying value.

Bear case

  1. Related-party credit risk: HK$230.7m owed by U-light Energy (≈18% of equity), unsecured by assets and due by 31 Dec 2026, guaranteed only by the controlling shareholder.

  2. Low-quality, non-recurring earnings: core operations lose money; profits depend on revaluation, interest, FX and tax credits, all of which can reverse.

  3. Governance discount is structural: repeated connected acquisitions and a controlling family stake of ≈56–60% mean discount-to-NAV may persist; liquidity is thin (≈34% float, low volumes).

Catalysts and monitorables (next 12 months)

MonitorableWhy it mattersTiming
Repayment/renewal of U-light Energy facilityLargest single credit exposure; drawdown period endsBy 31 Dec 2026
Completion of Jiangsu Yide acquisitionCash outflow ≈HK$137m; rental upliftPending (deposits paid HK$75.2m at 30 Jun 2026; link unconfirmed)
Further Alphington settlementsRevenue, cash, deleveragingH2 2026 – 2027
FY2026 PRC investment-property valuationMajor profit swing factorFY2026 results (≈Mar 2027)
Refinancing of HK$193m current borrowingsLiquidityRolling
Wingor Bio clinical readouts / financingEquity-investment valuationOngoing
Healthcare segment trajectoryStrategic credibilityFY2026 results
Buyback execution under 10% mandateSignal of NAV discount closureOngoing

Analyst verdict

Meilleure Health is a health company in name and narrative, but a property-and-credit vehicle in substance. Of HK$1.8bn in assets, roughly HK$680m is PRC investment property, HK$440–490m is a loan book half-owed by a related renewable-energy company, and HK$310m is Melbourne townhouse inventory; the healthcare operations that give the group its name hold about 1% of assets and lost money in FY2025. Revenue has fallen at a 38% compound rate over four years, and S&P-basis operating income has been negative since FY2024. That the company still reported HK$38m of profit in FY2025 and HK$28m in H1 2026 is a tribute to interest income, revaluation gains, FX translation and Australian settlements — real economic flows, but not the recurring, scalable franchise a health investor would want.

The valuation already reflects much of this. At HK$0.208, the market capitalisation of ≈HK$844m sits at 0.65x book, and the trailing dividend yield is ≈2.6% with ongoing buybacks. The H1 2026 interim shows the balance sheet turning: debt cut by HK$89m, net current assets up to HK$702m. If Alphington settlements continue and the U-light Energy facility is repaid on time at the end of 2026, the discount to NAV could narrow and distributions could rise.

The decisive variables are governance and credit rather than healthcare. The repeated pattern of related-party transactions — property purchases from the controlling shareholder's group, a large loan to a related company, a pending RMB125m acquisition from a Zhou-controlled vendor — means minority investors are exposed to decisions in which their interests and the controller's may diverge. Absent sell-side coverage, institutional ownership and quantified guidance, information asymmetry is high.

Verdict: a deep-value, special-situation NAV stock rather than a growth or healthcare play.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Board of Directors

NameRoleTenure (approx.)Background (public sources)Age

Mr. Zhou Xuzhou (周旭洲)

Executive Director, Co-Chairman; ultimate controlling shareholder

Chairman since Aug 2013

Founder of U-Home Group (宇業集團), Chuzhou Yuda Property Development and Huangshan Yulong Industry; director of U-Home Group International and Wuhu Meilleure; Wuhan University graduate (1985) [MS]

—

Dr. Zeng Wentao (曾文濤)

Executive Director, Co-Chairman

Since 20 Jun 2019

Founder of Hainan Sanyou Real Estate (1990) and Wuhan Yinhai Properties (1995); CEO of Zhongjia Capital (Wuhan) Investment Management since 2017; former Vice Chairman, Hubei Federation of Industry & Commerce; doctorate from Wuhan University [MS]

Born 1963 [WEBB]

Ms. Zhou Wen Chuan (周文川)

Executive Director, Vice-Chairman and CEO

CEO since 23 Sep 2013

University of British Columbia (bachelor's 2007, master's 2008); CUHK MBA (2011); director of Gongniu Group and Wingor Bio [MS]; described in company filings as an associate of Mr. Zhou Xuzhou [CT23]

≈41–42 [SWS]

Dr. Mao Zhenhua (毛振華)

Non-executive Director

—

Economist; founder and chairman of China Chengxin (credit rating) group; Wuhan University professor; multiple listed-company directorships [MS]

Born Jan 1964 [WEBB]

Prof. Chau Chi Wai, Wilton (周志偉)

Independent Non-executive Director

———

Mr. Chen Shi

Independent Non-executive Director

Appointed between Apr 2023 and Apr 2024 (replaced Dr. Yang Yu)

——

Mr. Wu Peng (吳鵬)

Independent Non-executive Director

——

Born 1982 [WEBB]

“—” = not publicly disclosed.

Directors' Remuneration

DirectorAuditRemunerationNominationStrategic

Zhou Xuzhou

——

Chair

Member

Zeng Wentao

—

Member

—

Member

Mao Zhenhua

Member

——

Chair

Chau Chi Wai, Wilton

Chair

Member

Member

—

Chen Shi

Member

Chair

——

Wu Peng

——

Member

—

Directors' Remuneration — Zhou Xuzhou

DirectorFeesSalary & benefitsRetirementShare-basedTotal

Zhou Xuzhou

080000800

Zhou Wen Chuan

01,20018-557661

Zeng Wentao

000-299-299

Mao Zhenhua

180000180

Chau Chi Wai, Wilton

180000180

Wu Peng

120000120

Gao Guanjiang (former INED)

5100051

Yang Yu (former INED)

00000

Total

5312,00018-8561,693

Major Shareholders

HolderSharesStakeSource / date

Zhou Xuzhou (via Shunda Investment Ltd and related vehicles)

2,310,076,761

≈56.4%

[MS], Apr 2024

Zhou Xuzhou (alternative aggregator figure)

—

≈59.7%

[SWS] (different date/denominator; discrepancy noted)

Zeng Wentao

—

≈1.85%

[SWS]

Zhou Wen Chuan

31,938,000

≈0.78%

[MS], Mar 2024

Total insiders

—

≈66.3%

[SA]

Institutions

—

≈2.8%

[SA]

Free float

≈1.37bn shares

≈34%

[SA]

Board & Management Changes

DateChange
2023

INEDs Gao Guanjiang and later Dr. Yang Yu departed; Mr. Chen Shi joined (by Apr 2024) [DIR23], [DIR24], [WEBB]

31 Dec 2025

Change of company secretary; change in nomination committee composition [MS]

21 Apr 2026

2026 Share Award Scheme adopted (10% scheme limit, 1% service-provider sublimit; 99.98% approval) [SGM26]

3 Jul 2026

5,328,000 awarded shares granted from treasury [IR26]

Competitive Landscape

Competitors by Segment

SegmentCompetitorRelative positioning (qualitative unless stated)

Recombinant collagen / efficacy skincare

Giant Biogene (2367.HK)

—

Hyaluronic acid / functional skincare

Bloomage Biotech (688363.SH)

—

Injectable aesthetics

Imeik Technology (300896.SZ)

—

Medical aesthetics clinics (HK/PRC)

Perfect Medical Health Management (1830.HK)

—

Medical aesthetics clinics

Miricor Enterprises (1827.HK)

—

Medical aesthetics chains (private)

BeauCare Clinics (聯合麗格) — also a channel partner

Large private chain; not publicly disclosed

Aesthetics platform

So-Young International (NASDAQ: SY)

—

Cell therapy (investee competitors)

Shanghai Cellular Biopharmaceutical, Hrain Biotech, other NMPA MSC IND sponsors

Wingor Bio is a small private player

CBD wellness (Europe)

Charlotte's Web (TSX: CWEB), numerous private EU brands

AlpReleaf is niche (Europe revenue HK$1.2m in FY2025)

PRC commercial leasing

Local landlords and developers in Jiangsu/Anhui

Meilleure is a price-taker with ≈HK$19m rent

Melbourne townhouse development

Local Australian developers

Single project

Peer Comparison FY2025

MetricMeilleure Health FY2025Giant Biogene FY2024Bloomage FY2024Imeik FY2024

Revenue

HK$36.5m

≈RMB5.5bn

≈RMB5.4bn

≈RMB3.0bn

Revenue growth

−27.9%

Strong double-digit growth

Decline

Decline

Gross margin

62.0%

≈80%+

≈70%+

≈90%+

R&D intensity

—

Disclosed (mid-single-digit %)

Disclosed (high-single-digit %)

Disclosed (≈10%+)

“—” = not publicly disclosed.

Recent Developments

Headcount moved from 46 (end-2024) to 42 (end-2025) to 43 (mid-2026).

Company Snapshot

$4.7M

Revenue

43

Employees

$108M

Market Cap

1987

Founded

Admiralty, Hong Kong

Headquarters

SWOT Analysis

Strengths

  • Substantial asset backing: equity attributable to owners of HK$1,303.3m at 30 Jun 2026 vs market capitalisation ≈HK$844m (0.65x P/B) [IR26], [SA].
  • Recurring rental income: HK$19.2m in FY2025 (+11.4%), from PRC investment properties fair-valued at HK$663.4m [AR25].
  • High-yielding loan book: interest income HK$29.3m in FY2025 (+33%), loans at 3–8% and LPR+3.05% [AR25].
  • Australian project now monetising: HK$151.9m of settlements in H1 2026, enabling HK$146.1m of debt repayment [IR26].
  • Consistent profitability and dividends: profit in every year FY2021–FY2025; FY2025 total DPS HK0.55 cents, ≈2.6% trailing yield [AR25], [SA].
  • Clean audit and compliance record: unqualified opinion from ZHONGHUI ANDA; no material litigation at end-2025 [AR25].

Weaknesses

  • Collapsing core revenue: −38.4% CAGR FY2021–FY2025 [SA], [AR25].
  • Operating losses: S&P-basis operating loss of HK$9.7m in FY2025; opex ≈HK$31m exceeds gross profit [SA], [AR25].
  • Low-quality earnings: FY2025 profit relied on interest (HK$29.3m), revaluation (HK$21.7m), FX (HK$8.4m) and a HK$7.5m tax credit [AR25].
  • Thin liquidity: cash of HK$7.8m at 30 Jun 2026 with HK$193.2m of borrowings due within one year and no unutilised facilities [IR26].
  • Healthcare sub-scale and shrinking: segment revenue HK$16.1m (FY2025) and HK$4.4m (H1 2026, −33%) [AR25], [IR26].
  • Low returns: ROE ≤4.2% throughout FY2021–FY2025 (computed).

Opportunities

  • Remaining Alphington inventory: HK$310.6m carrying value still to be settled, potentially funding further deleveraging [IR26].
  • Jiangsu Yide acquisition: adds ≈RMB7.8m of annual rent (≈40% uplift on FY2025 rent) [JY26].
  • Wingor Bio pipeline: 7 INDs accepted and 3 in clinical trials; China's 2025 cell-therapy regulatory framework could support valuation re-rating [AR25], [IR26].
  • Policy support for health consumption and ageing care (2025 action plans; 15th FYP National Health Plan) [AR25], [IR26].
  • Recombinant collagen and exosome skincare trends via Jland Biotech and exosome series [AR25].
  • Capital returns: buyback authority up to 10% of shares while trading below book [MS].

Threats

  • Related-party credit concentration: U-light Energy loan HK$230.7m (52.3% of loans; ≈18% of equity), due by 31 Dec 2026, unsecured by assets [IR26].
  • Counterparty defaults: RMB7.1m Yunnan Hansu consideration written off in 2025 [AR25].
  • PRC property valuation risk: HK$678.3m of investment property with HK$509.1m pledged [IR26].
  • Refinancing risk: HK$271.3m of debt was current at end-2025 [AR25].
  • Regulatory tightening in medical aesthetics (Feb 2025 guiding opinions) [AR25].
  • Minority-shareholder risk: controlled company with recurring connected acquisitions (2023 properties, 2024 Kunshan units, 2026 Jiangsu Yide) [CT23], [JY26].

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
Mar 2025Wingor Bio granted two CNIPA invention patents; elected Vice President Unit of Shenzhen Biological Medicine Promotion AssociationInvestee IP progress
Apr 2025Mei Ai Kang reaches 132 completed clinical experimentsInvestee progress
27 Jun 2025AGM approves general mandates incl. 10% buyback mandateEnables 2026 buyback
Jul 2025Wingor Bio reports positive interim WG103 AIS data; starts Phase IIInvestee pipeline milestone
8 Aug 2025Wingor Bio granted AI cell-culture monitoring patentIP
Aug 2025Wingor Bio raises tens of millions of RMBSupports valuation of stake
15 Aug 2025Positive profit alert: H1 2025 profit HK$14–16mEarnings guidance
28 Aug 2025H1 2025 results: revenue HK$17.5m (−41.9%), profit HK$15.1m (+79–84%); first interim dividend HK0.15 centsProfit driven by interest, FX and absence of revaluation loss
Oct 2025Wingor Bio wins three awards at 9th Asia Cell & Gene Therapy Innovation SummitInvestee profile
31 Oct 2025Interim dividend paidDistribution
6 Nov 20256.11% shareholding transferred between CCASS brokers (HK$68.8m)Watch for ownership change
Nov 2025Wingor Bio adaptive cell-thawing patentIP
31 Dec 2025Company secretary and nomination committee changesGovernance
7 Jan 2026Buyback programme of up to 409.4m shares announcedCapital return
8 Jan 2026Connected acquisition of Jiangsu Yide for RMB124.8mRental expansion; related-party risk
Jan 2026Wingor Bio MSC injection (POI) approved for clinical trials; cell-bank standard releasedInvestee milestone
27 Mar 2026FY2025 results: revenue HK$36.5m (−27.9%), attributable profit HK$38.0m (+16.9%), final dividend HK0.4 centsEarnings
Apr 2026Wingor Bio signs CGT clinical research agreement with Zhuhai People's HospitalInvestee
21 Apr 2026SGM approves Jiangsu Yide acquisition and 2026 Share Award SchemeCorporate action
H1 2026Cancellation of 33.07m treasury shares; repurchase of 7.5m shares (HK$2.04m)Capital return
H1 2026First-phase Alphington handoversRevenue inflection
May 2026Soft agar colony formation assay standard (Wingor-led) releasedInvestee
26 Jun 2026AGM approves FY2025 final dividendDistribution
3 Jul 2026Grant of 5,328,000 award sharesIncentives
7 Jul 2026Positive profit alert: H1 2026 profit ≥HK$27.0mGuidance
Jul 2026Wingor Bio's seventh stem-cell IND acceptedInvestee
27 Aug 2026H1 2026 results: revenue HK$164.6m (+840.6%), profit HK$28.3m (+87%), interim dividend HK0.15 cents; debt cut to HK$291.0mInflection; deleveraging
28 Aug 2026FY2025 final dividend (≈HK$16.2m) paidDistribution
30 Sep 2026Interim dividend (≈HK$6.1m) paidDistribution
9 Oct 2026Share price HK$0.208, −27% over 52 weeksMarket sentiment weak despite earnings growth

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

6 charts
Income Statement: Revenue & Gross Profit: Revenue fell from HKD 253 Mn in FY2021 to HKD 36.5 Mn in FY2025.
Meilleure Health International Industry Group Limited — Income Statement: Revenue & Gross Profit
Series (HKD Mn)FY2021FY2022FY2023FY2024FY2025
Revenue253119.9129.350.736.5
Gross profit100.966.877.228.922.6

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.